adagrasib KRAS G12C
Selected indexed studies
- Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRAS(G12C) Mutation. (N Engl J Med, 2022) [PMID:35658005]
- Adagrasib in Advanced Solid Tumors Harboring a KRAS(G12C) Mutation. (J Clin Oncol, 2023) [PMID:37099736]
- Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C. (N Engl J Med, 2023) [PMID:36546659]
_Worker-drafted node — pending editorial review._
Connections
adagrasib KRAS G12C is a side effect of
Sources
- Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRAS(G12C) Mutation. (2022) pubmed
- Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C. (2023) pubmed
- Adagrasib in Advanced Solid Tumors Harboring a KRAS(G12C) Mutation. (2023) pubmed
- Adagrasib versus docetaxel in KRAS(G12C)-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial. (2025) pubmed
- Adagrasib: a novel inhibitor for KRAS(G12C)-mutated non-small-cell lung cancer. (2023) pubmed
- Acquired Resistance to KRAS(G12C) Inhibition in Cancer. (2021) pubmed
- KRAS G12C in advanced NSCLC: Prevalence, co-mutations, and testing. (2023) pubmed
- The KRAS(G12C) Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients. (2020) pubmed
- First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRAS(G12C) Solid Tumors (KRYSTAL-1). (2022) pubmed
- Diverse alterations associated with resistance to KRAS(G12C) inhibition. (2021) pubmed